Yescarta Uniunea Europeană - română - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenți antineoplazici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

GLUCOTHERA 1,4 m/v GLUCOZA România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

glucothera 1,4 m/v glucoza

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

GLUCOTHERA 2,4 m/v GLUCOZA România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

glucothera 2,4 m/v glucoza

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

GLUCOTHERA 4 m/v GLUCOZA România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

glucothera 4 m/v glucoza

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Abecma Uniunea Europeană - română - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenți antineoplazici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.